Bionano Genomics (BNGO) Asset Writedowns and Impairment (2018 - 2024)

Bionano Genomics has disclosed Asset Writedowns and Impairment across 5 years of filings, most recently posting -$400000.0 for Q4 2024.

• Asset Writedowns and Impairment for Q4 2024 came in at -$400000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $6.8 million (down 5.56% YoY), and the FY2024 annual result was $7.2 million, changed N/A from the prior year.
• Asset Writedowns and Impairment came in at -$400000.0 for Q4 2024 at Bionano Genomics, down from $7.2 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $7.2 million in Q3 2024 to a low of -$400000.0 in Q4 2024.
• The 3-year median for Asset Writedowns and Impairment is $433000.0 (2020), against an average of $1.2 million.
• Peak annual rise in Asset Writedowns and Impairment reached 16.02% in 2020, while the deepest fall reached 16.02% in 2020.
• Bionano Genomics' Asset Writedowns and Impairment stood at $466000.0 in 2020, then surged by 32.19% to $616000.0 in 2022, then tumbled by 164.94% to -$400000.0 in 2024.
• The last three Asset Writedowns and Impairment figures came in at -$400000.0 (Q4 2024), $7.2 million (Q3 2024), and $400000.0 (Q1 2024), per Business Quant data.